Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimized voriconazole dosing for invasive pulmonary aspergillosis in acute-on-chronic liver failure
ChiCTR2100048259Phase 4Recruiting
- Sponsor
- The Third Affiliated Hospital of Sun Yat-sen University
- Start
- Aug 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of voriconazole in Acute Invasive Aspergillosis (2 arms), sponsored by The Third Affiliated Hospital of Sun Yat-sen University. Primary endpoints: Antifungal effect and Voriconazole plasma concentration. Started Aug 2021; status: recruiting.
02
Drugs
voriconazole
03
Conditions
Acute Invasive Aspergillosis
Beyond the preview
Go deeper on ChiCTR2100048259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100048259.